North America Stem Cell Therapy Market Key Players Analysis, Opportunities and Growth Forecast to 2028
The North America stem cell therapy market was valued at US$ 1,299.39 million in 2022 and is projected to reach US$ 3,582.26 million by 2028; it is expected to grow at a CAGR of 18.4% from 2022 to 2028.
Increasing Research Activities Related
to Stem Cell Therapy for Effective Disease Management is Driving the North
America Stem Cell Therapy Market
Stem cell therapy has been widely investigated across the world.
Stem cells are mainly used to replace dying cells and reconstruct damaged
tissues. Based on the results of extensive stem cell research conducted so far,
many scientists have claimed that these cells could probably be utilized to
generate cures and treatments for diseases such as cancer and cardiovascular
disease. Newly developed stem cell therapies involve replacing disease-causing
cells with stem cells. Many potential treatments involving stem cells are in
different phases of clinical trials. The FDA has also approved a few stem cell
therapies involved in treating complications related to stem cell transplants.
In September 2021, the US Food and Drug Administration (FDA) announced approval
for "Ruxolitinib" for treating "graft-versus-host-disease"
(GVHD) in patients aged 12 and above. Ruxolitinib provides a patient new hope
that suffers from fatal complications associated with stem cell transplants.
๐๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐
๐๐๐ฆ๐ฉ๐ฅ๐
๐๐๐
๐๐จ๐ฉ๐ฒ@
https://www.businessmarketinsights.com/sample/BMIRE00028486
Researchers are further investigating the use of stem cell therapy
in treating autoimmune disorders. For example, stem cells can turn into the
cells of damaged organs and are used in treating autoimmune diseases. Treatment
is carried out using mesenchymal stem cells or fetal stem cells. Hematopoietic
stem cells are currently used for treating more than 80 medicals conditions,
including immune system diseases, blood disorders, neurological disorders,
metabolic disorders, genetic disorders, and cancer types such as leukemia and
lymphoma.
๐๐ก๐ ๐๐ข๐ฌ๐ญ
๐จ๐
๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ
MEDIPOST
RichSource
BioTime, Inc.
Mesoblast Limited
U.S. Stem Cell, Inc.
TiGenix NV
AlloSource
NuVasive Inc
๐๐
๐ฎ๐ฅ๐ฅ
๐๐๐ฉ๐จ๐ซ๐ญ
๐๐ข๐ง๐ค
@ https://www.businessmarketinsights.com/reports/north-america-stem-cell-therapy-market
ยท
Segments Covered
By Type
- Adult
Stem Cell Therapy
- Embryonic
Stem Cell Therapy
- Induced
Pluripotent Stem Cell Therapy
- Other
Stem Cell Therapy
By Treatment
- Allogeneic
- Autologous
By Application
- Musculoskeletal
- Dermatology
- Cardiology
- Drug
Discovery & Development
- Other
Applications
By End User
- Hospitals
& Specialty Clinics
- Academic
& Research Institutes
The
Ascendant Tide: Navigating the North American Stem Cell Therapy Market
The North American stem cell therapy
market is a dynamic and rapidly evolving landscape, driven by groundbreaking
scientific advancements, increasing clinical applications, and a growing
patient population seeking innovative treatment options. This market,
encompassing the United States, Canada, and Mexico, is poised for significant
expansion in the coming years, fueled by substantial investments in research
and development, coupled with a rising awareness of the therapeutic potential
of stem cells.
A Foundation Built on Innovation:
North America has long been at the
forefront of stem cell research, with pioneering institutions and researchers
laying the groundwork for the field's current state. The region boasts a robust
ecosystem of academic centers, biotechnology companies, and clinical research
organizations dedicated to exploring the vast potential of stem cells. This
commitment to innovation has resulted in a steady stream of scientific
breakthroughs, translating into novel therapies for a range of debilitating
diseases.
Comments
Post a Comment